Claude on the Cannabis Decision
Today’s deadline is a filing deadline, not a decision point. October 13 is a filing deadline, not a scheduled restart or decision date. Chief ALJ Derek Julius set no deadline for a ruling on the motion or for a recommended decision. I couldn’t find reporting yet on what was actually filed today, so what follows is my read of the likely paths. mgmagazinemugglehead
What’s being decided: The order directs the government and other participants to respond to a motion seeking to introduce the newly released GAO report into the administrative record. The government’s response may run up to 20 pages. Other designated participants may respond under the same specifications but aren’t required to. gmlawkindgreenbuds
Likely outcomes after the filings
- The judge denies the motion and lifts the stay. This is the path the industry commentary seems to expect. The GAO report predates these rescheduling proceedings, does not target cannabis explicitly, and did not conclude that the agencies violated the law or reject the scientific findings supporting Schedule III placement. The judge would then resume work on his non-binding recommendation to the DEA Administrator. gmlaw
- The judge admits the report but doesn’t allow more briefing. The report goes into the record and the case resumes, with the report’s weight left for later stages.
- The judge admits the report and allows supplemental briefing. This is what the movants want. It would delay his recommendation further, since the proceeding stays paused while the parties file additional briefs.
- The judge reopens the record more broadly. This is the least likely and most disruptive path. The movants argue that the proper course is a new evaluation under a written standard, not a final rule on this record. The judge could decide the GAO findings justify more than a short supplement, though nothing so far suggests he’s leaning that way. ndasa
What the government is likely to argue: The GAO report found that for all 84 substances with final rules requiring a federal health recommendation, DEA’s decisions aligned with the recommendation. The agencies also concurred with GAO’s recommendations for written policies and an updated FDA–NIH agreement. That gives them room to argue the report is procedural, not substantive, and doesn’t undermine the Schedule III findings. I can’t confirm that’s the position they took in their filing. muggleheadkindgreenbuds
What doesn’t change: Whatever happens, April’s separate medical-cannabis order is unaffected. Even after the judge resumes, his recommendation is only a step toward agency action, rather than the final rule itself. The DEA Administrator still has to act. mgmagazinekindgreenbuds
Position: None
